Biodistribution and radioimmunotherapy of SCCHN in xenotransplantated SCID mice with a 131I-labelled anti-EpCAM monoclonal antibody

Anticancer Research

Volumn 27, Issue 1 A, 2007, Pages 431-436

  Andratschke, Michaela ^a,c   Gildehaus, Franz Josef ^a   Johannson, Veronika ^a   Schmitt, Baerbel ^a   Mack, Brigitte ^a   Reisbach, Gilbert ^b   Lang, Stephan ^c   Lindhofer, Horst ^d   Zeidler, Reinhard ^a   Wollenberg, Barbara ^c   Luebbers, Christian W ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d Trion Pharma Inc   (Germany)

Author keywords

C215; EpCAM; Radio labeled monoclonal antibody; Radioimmunotherapy; SCCHN; SCID mice

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; EPITHELIAL CELL ADHESION MOLECULE MONOCLONAL ANTIBODY; EPITHELIAL CELL ADHESION MOLECULE MONOCLONAL ANTIBODY I 131; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C215; MONOCLONAL ANTIBODY C215 I 131; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; HEAD AND NECK CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SQUAMOUS CELL CARCINOMA; XENOTRANSPLANTATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CELL ADHESION MOLECULES; HUMANS; HYPOPHARYNGEAL NEOPLASMS; IMMUNOGLOBULIN G; IMMUNOTOXINS; IODINE RADIOISOTOPES; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 33847616231     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Parkin DM, Bray F, Ferlay I and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55(2): 74-108, 2005
2. Wollenberg B, Walz A, Kolbow K, Pauli C, Chaubal S and Andratschke M: Clinical relevance of circulating tumour cells in the bone marrow of patients with SCCHN. Onkologie 27: 358-362, 2004.
3. Pignon JP, Bourhis J, Domenge C and Designe L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355(9208): 949-955, 2000.
4. Forastiere AA: Is there a new role for induction chemotherapy in the treatment of head and neck cancer? J Natl Cancer Inst 96(22): 1647-1649, 2004.
5. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, Stagg R, Tidmarsch G and Wahl RL: Radioimmunotherapy with iodine 131-I tositumomab for relapsed or refractory B-cell non Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96: 1259-1266, 2000.
6. Stroomer JW, Roos JC, Sproll M, Quak JJ, Heider KH, Wilhelm BJ, Castelijns JA, Meyer R, Kwakkelstein MO, Snow GB, Adolf GR and Van Dongen GAMS: Safety and biodistribution of 99m-technetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin Cancer Res 6: 3046-3055, 2000.
7. Balzar M, Winter MJ, de Boer CJ and Litvinov SV: The biology of the 17-1A antigen (Ep-CAM). J Mol Med 77(10): 699-712, 1999.
8. Quak JJ, Balm AJ, van Dongen GA, Brakkee JG, Scheper RJ, Snow GB and Meijer CJ: A 22-kd surface antigen detected by monoclonal antibody E 48 is exclusively expressed in stratified squamous and transitional epithelia. Am J Pathol 136(1): 191-197, 1990.
9. Litvinov SV, van Driel W, van Rhijn CM, Bakker HA, van Krieken H, Fleuren GJ and Warnaar SO: Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Am J Pathol 148(3): 865-875, 1996.
10. Andratschke M, Hagedorn H, Luebbers CW, Schmitt B, Lang S, Zeidler R and Wollenberg B: Limited suitability of EpCAM for molecular staging of tumor borders in head and neck cancer. Anticancer Res 26(1A): 153-158, 2006.
11. Chaubal S, Wollenberg B, Kastenbauer E and Zeidler R: Ep-CAM - a marker for the detection of disseminated tumor cells in patients suffering from SCCHN. Anticancer Res 19(3B): 2237-2242, 1999.
12. Riethmüller G, Schneider Gadicke E, Schlimock G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R et al: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 343: 1177-1183, 1994.
13. Riethmüller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Funke I, Pichlmaier H, Hirche H, Buggisch P, Witte J and Pichlmary R: Monoclonal antibody therapy for resected Dukes'C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 16: 1788-1794, 1998.
14. Weadock KS, Sharkey RM, Varga DC and Goldenberg DM: Evaluation of a remote radioiodination system for radio-immunotherapy. J Nucl Med 31(4): 508-511, 1990.
15. Postema EJ, Boerman OC, Oyen WJ, Raemaekers JM and Corstens FH: Radioimmunotherapy of B-cell non Hodgkin's lymphoma. Eur J Nucl Med 28: 1725-1735, 2001.
16. Tsai SW, Sun YY, Williams LE, Raubitschek AA, Wu AM and Shively JE: Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5. Bioconjug Chem 11(3): 327-334, 2000.
17. 2a serum concentrations. Cancer Immunol Immunother 46(1): 25-33, 1998.
18. 2a in SCID mice. Cancer Immunol Immunother 51(10): 547-556, 2002.
19. Naundorf S, Preithner S, Mayer P, Lippold S, Wolf A, Hanakam F, Fichtner I, Kufer P, Raum T, Riethmüller G, Bäuerle P and Dreier T: In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer 100: 101-110, 2002.
20. Goldenberg DM: Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother 52(5): 281-296, 2003.
21. Van Dongen GA, Visser GW and Vrouenraets MB: Photosensitizer-antibody conjugates for detection and therapy of cancer. Adv Drug Deliv Rev 56(1): 31-52, 2004.